StockSelector.com
  Research, Select, & Monitor Sunday, August 25, 2019 9:23:44 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Exact Sciences Corp.$116.96($.91)(.77%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Exact Sciences Corp. vs Biotechnology

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.




An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
 Totals Company Industry
  Sales: $454.5 Mil $96,521.2 Mil
  Market Cap: $15,109.1 Mil $454,685.3 Mil
  Analysts Recommendation: Strong Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: 70.9% 94.6%
  Estimated Revenue: 78.2% 34.5%
  Historic Earnings: N/A (10.0%)
  Estimated Earnings: N/A 11.5%
  Stock Price (1 Year): 72.1% 11.5%
  Cash per Share: 101.7% 10.9%
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: N/A 40.5
  Price-to-Sales: 24.2 N/A
  Price-to-Book: 21.1 4.7
  Dividend Yield: N/A N/A
  Market Cap: $15,109.1 Mil $10,825.8 Mil
  Operations
  Net Margin: (34.1%) (651.4%)
  Gross Margin: 74.0% 72.3%
  Return on Equity: (.3) (.5)
  Return on Assets: (.1) (.3)
  Balance Sheet
  Current Ratio: 9.0 6.5
  Quick Ratio: 8.7 6.1
  Cash Ratio: 8.2 5.0
  Debt-to-Equity: 1.2 1.3
  Interest Coverage: .6 1.1
 Technicals
  Relative-Strength Index: 49.3 46.1

 Other companies in Biotechnology Price Market Cap
  Amgen, Inc.  (AMGN) $199.08 $121,438.8 Mil
  Gilead Sciences, Inc.  (GILD) $62.51 $79,825.3 Mil
  Celgene Corp.  (CELG) $93.99 $68,302.5 Mil
  Biogen Inc.  (BIIB) $225.85 $43,001.8 Mil
  Regeneron Pharmaceuticals Inc.  (REGN) $286.85 $32,873.0 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.